Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by D. E. Shaw & Co. Inc.

D. E. Shaw & Co. Inc. cut its holdings in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 45.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 304,146 shares of the biopharmaceutical company’s stock after selling 255,652 shares during the period. D. E. Shaw & Co. Inc. owned approximately 0.52% of Vanda Pharmaceuticals worth $1,457,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. XTX Topco Ltd bought a new stake in Vanda Pharmaceuticals during the 4th quarter valued at $69,000. Zacks Investment Management acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter valued at $74,000. Price T Rowe Associates Inc. MD raised its stake in shares of Vanda Pharmaceuticals by 17.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 3,370 shares in the last quarter. Tudor Investment Corp ET AL raised its stake in shares of Vanda Pharmaceuticals by 59.5% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 9,180 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in Vanda Pharmaceuticals by 26.8% in the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 5,459 shares during the period. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were acquired at an average price of $4.46 per share, for a total transaction of $44,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 2,331,730 shares of the company’s stock, valued at $10,399,515.80. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased a total of 60,000 shares of company stock valued at $270,800 over the last three months. Insiders own 8.90% of the company’s stock.

Vanda Pharmaceuticals Trading Down 1.9%

Shares of NASDAQ VNDA opened at $4.24 on Friday. Vanda Pharmaceuticals Inc. has a twelve month low of $3.81 and a twelve month high of $6.75. The firm has a 50-day moving average of $4.38 and a two-hundred day moving average of $4.62. The company has a market capitalization of $249.88 million, a price-to-earnings ratio of -13.25 and a beta of 0.69.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.55) by $0.05. The business had revenue of $50.04 million for the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. As a group, research analysts predict that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on VNDA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 14th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th. Finally, Wall Street Zen started coverage on Vanda Pharmaceuticals in a research report on Wednesday, February 5th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.